Fig 1: The apoCIIIHDL ratio (apoCIIIHDL over plasma apoCIII) between CAD (n = 140) and nonCAD (n = 99) patients. Data are expressed as mean ± SD. ApoCIIIHDL indicates apolipoprotein CIII in apoB-depleted plasma; apoB, apolipoprotein B; CAD, coronary artery disease. **P < 0.01.
Fig 2: Comparison of circulating ANGPTL8 and apoCIII concentrations under different baseline conditons. Data are expressed as median(interquartile range). a. ANGPTL8 concentration in the low apoCIII group and high apoCIII group. b. Triglyceride level in the low apoCIII group and high apoCIII group. ApoCIII indicates apolipoprotein CIII; TG, triglyceride; ANGPTL8, angiopoietin-like protein
Fig 3: ELISA validation of APOA1, APOC3, Adiponectin and PCSK9 in another cohort. (A) The concentration comparison and (B) ROC analysis of APOA1, APOC3, Adiponectin and PCSK9 between CGE patients and healthy controls.
Fig 4: The correlation between plasma apoCIII (log transformed) and triglyceride in all the subjects (n = 239). ApoCIII indicates apolipoprotein CIII; TG, triglyceride.
Fig 5: Pearson’s correlations between clinical variables and log-transformed ANGPTL8 as well as log-transformed apoCIII in all the subjects. a. ANGPTL8 and TG. b. ApoCIII and TG. c. ANGPTL8 and apoCIII. TG indicates triglyceride; ANGPTL8, angiopoietin-like protein; apoCIII, apolipoprotein CIII
Supplier Page from Abcam for Human Apolipoprotein CIII ELISA Kit (APOC3)